Filing of the 2012 U.S. Form 20-F and French “Document de Référence” containing the Annual Financial Report

PR Newswire/Les Echos/ 
PRESS RELEASE 
 Filing of the 2012 U.S. Form 20-F and French " Document de Référence " 
                 containing the Annual Financial Report 
Paris, France - March 8, 2013 - Sanofi (EURONEXT: SAN and NYSE: SNY) announced
today the filing of its Form 20-F with the U.S. Securities and Exchange 
Commission (SEC) and its "Document de Référence" containing its Annual 
Financial Report with the French market regulator Autorité des marchés 
financiers (AMF). 
These documents are available on the "Investors" page of the company's 
corporate website (www.sanofi.com) under the heading "Regulated Information in 
France." In addition, the Form 20-F is available on the website of the SEC 
(www.sec.gov), and the "Document de Référence" is available on the website of 
the AMF (www.amf-france.org). Shareholders may receive a hard copy of these 
documents, each of which contains our complete audited financial statements, 
free of charge, upon request. 
About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris 
(EURONEXT: SAN) and in New York (NYSE: SNY). 
Contacts: 
Media Relations                      Investor Relations
Jean-Marc Podvin                     Sébastien Martel
Tel.: + (33) 1 53 77 46 46           Tel.: + (33) 1 53 77 45 45
mr@sanofi.com                        ir@sanofi.com 
                  
The content and accuracy of news releases published on this site and/or 
distributed by PR Newswire or its partners are the sole responsibility of the 
originating company or organisation. Whilst every effort is made to ensure the 
accuracy of our services, such releases are not actively monitored or reviewed 
by PR Newswire or its partners and under no circumstances shall PR Newswire or 
its partners be liable for any loss or damage resulting from the use of such 
information. All information should be checked prior to publication. 
-0- Mar/11/2013 07:11 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.